OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
|Videos|July 29, 2021
Dr. Helfand on how genomic testing provides real-time status of prostate tumor
Author(s)Urology Times staff
Advertisement
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”
Advertisement
Related to this article
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Advertisement
Advertisement